Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study.
(18)F-FDG PET/CT
Cachexia
Cancer
Nutritional support
Supportive care
Tumour growth
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
14
03
2018
revised:
16
07
2018
accepted:
25
08
2018
pubmed:
14
9
2018
medline:
26
9
2020
entrez:
14
9
2018
Statut:
ppublish
Résumé
Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by This prospective study included ten patients with histologically proven head and neck or oesophageal cancer. All patients underwent Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16-45.90], protein intake of 0.84 g/kg/day [0.56-1.64]) was administered. Eight patients (80%) received enteral nutrition and two patients (20%) parenteral support. Comparison of In cachexic patients with head and neck or oesophageal cancer, nutrition support administered according to the current guidelines shows no impact on tumour glucose metabolism, assessed by
Sections du résumé
BACKGROUND & AIMS
Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by
METHODS
This prospective study included ten patients with histologically proven head and neck or oesophageal cancer. All patients underwent
RESULTS
Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16-45.90], protein intake of 0.84 g/kg/day [0.56-1.64]) was administered. Eight patients (80%) received enteral nutrition and two patients (20%) parenteral support. Comparison of
CONCLUSIONS
In cachexic patients with head and neck or oesophageal cancer, nutrition support administered according to the current guidelines shows no impact on tumour glucose metabolism, assessed by
Identifiants
pubmed: 30209026
pii: S0261-5614(18)32427-0
doi: 10.1016/j.clnu.2018.08.033
pii:
doi:
Substances chimiques
Blood Glucose
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2121-2126Informations de copyright
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.